Biomarkers in Randomized Clinical Trials

Magnetic Resonance Imaging

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: It is essential that randomized clinical trials (RCTs) incorporate biomarkers of disease progression that would be sensitive to the effects of disease-modifying treatments. Magnetic resonance imaging (MRI) can be safely repeated over time, and is routinely performed in clinical centers, making it an ideal modality to be incorporated into RCTs. Summary: This chapter discusses potential structural MRI biomarkers that have been proposed for a number of different neurodegenerative disorders, including Alzheimer's disease (AD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), progressive supranuclear palsy syndrome (PSPS), and Parkinson's disease (PD). All of these disorders represent targets for ongoing and future RCTs. Rates of hippocampal atrophy and ventricular expansion provide excellent biomarkers of disease progression in AD, and may also provide biomarkers in prodromal and preclinical phases of the disease, as well as in DLB. Rates of ventricular expansion also perform well in FTD, although regional frontal and temporal measurements could also be useful. Rates of midbrain atrophy provide the most feasible MRI biomarker in PSPS. In contrast, PD is not associated with specific patterns of cerebral atrophy and further work is needed in order to define useful MRI biomarkers. Sample size calculations using these MRI biomarkers are presented and discussed. Key Messages: Rates of cerebral atrophy provide valuable potential biomarkers of disease progression in neurodegenerative disorders, and have already begun to be utilized as outcome measures in RCTs. Measurements from other structural and functional MRI modalities require more longitudinal validation, but may prove to be useful in the future.

Original languageEnglish (US)
Pages (from-to)101-108
Number of pages8
JournalFrontiers of Neurology and Neuroscience
Volume39
DOIs
StatePublished - 2016

Fingerprint

Randomized Controlled Trials
Biomarkers
Magnetic Resonance Imaging
Atrophy
Progressive Supranuclear Palsy
Disease Progression
Lewy Body Disease
Frontotemporal Dementia
Alzheimer Disease
Neurodegenerative Diseases
Parkinson Disease
Mesencephalon
Sample Size
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Biomarkers in Randomized Clinical Trials : Magnetic Resonance Imaging. / Whitwell, Jennifer Lynn.

In: Frontiers of Neurology and Neuroscience, Vol. 39, 2016, p. 101-108.

Research output: Contribution to journalArticle

@article{cfe0328dda8846f684a6f840560cfe5a,
title = "Biomarkers in Randomized Clinical Trials: Magnetic Resonance Imaging",
abstract = "Background: It is essential that randomized clinical trials (RCTs) incorporate biomarkers of disease progression that would be sensitive to the effects of disease-modifying treatments. Magnetic resonance imaging (MRI) can be safely repeated over time, and is routinely performed in clinical centers, making it an ideal modality to be incorporated into RCTs. Summary: This chapter discusses potential structural MRI biomarkers that have been proposed for a number of different neurodegenerative disorders, including Alzheimer's disease (AD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), progressive supranuclear palsy syndrome (PSPS), and Parkinson's disease (PD). All of these disorders represent targets for ongoing and future RCTs. Rates of hippocampal atrophy and ventricular expansion provide excellent biomarkers of disease progression in AD, and may also provide biomarkers in prodromal and preclinical phases of the disease, as well as in DLB. Rates of ventricular expansion also perform well in FTD, although regional frontal and temporal measurements could also be useful. Rates of midbrain atrophy provide the most feasible MRI biomarker in PSPS. In contrast, PD is not associated with specific patterns of cerebral atrophy and further work is needed in order to define useful MRI biomarkers. Sample size calculations using these MRI biomarkers are presented and discussed. Key Messages: Rates of cerebral atrophy provide valuable potential biomarkers of disease progression in neurodegenerative disorders, and have already begun to be utilized as outcome measures in RCTs. Measurements from other structural and functional MRI modalities require more longitudinal validation, but may prove to be useful in the future.",
author = "Whitwell, {Jennifer Lynn}",
year = "2016",
doi = "10.1159/000445419",
language = "English (US)",
volume = "39",
pages = "101--108",
journal = "Frontiers of Neurology and Neuroscience",
issn = "1660-4431",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Biomarkers in Randomized Clinical Trials

T2 - Magnetic Resonance Imaging

AU - Whitwell, Jennifer Lynn

PY - 2016

Y1 - 2016

N2 - Background: It is essential that randomized clinical trials (RCTs) incorporate biomarkers of disease progression that would be sensitive to the effects of disease-modifying treatments. Magnetic resonance imaging (MRI) can be safely repeated over time, and is routinely performed in clinical centers, making it an ideal modality to be incorporated into RCTs. Summary: This chapter discusses potential structural MRI biomarkers that have been proposed for a number of different neurodegenerative disorders, including Alzheimer's disease (AD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), progressive supranuclear palsy syndrome (PSPS), and Parkinson's disease (PD). All of these disorders represent targets for ongoing and future RCTs. Rates of hippocampal atrophy and ventricular expansion provide excellent biomarkers of disease progression in AD, and may also provide biomarkers in prodromal and preclinical phases of the disease, as well as in DLB. Rates of ventricular expansion also perform well in FTD, although regional frontal and temporal measurements could also be useful. Rates of midbrain atrophy provide the most feasible MRI biomarker in PSPS. In contrast, PD is not associated with specific patterns of cerebral atrophy and further work is needed in order to define useful MRI biomarkers. Sample size calculations using these MRI biomarkers are presented and discussed. Key Messages: Rates of cerebral atrophy provide valuable potential biomarkers of disease progression in neurodegenerative disorders, and have already begun to be utilized as outcome measures in RCTs. Measurements from other structural and functional MRI modalities require more longitudinal validation, but may prove to be useful in the future.

AB - Background: It is essential that randomized clinical trials (RCTs) incorporate biomarkers of disease progression that would be sensitive to the effects of disease-modifying treatments. Magnetic resonance imaging (MRI) can be safely repeated over time, and is routinely performed in clinical centers, making it an ideal modality to be incorporated into RCTs. Summary: This chapter discusses potential structural MRI biomarkers that have been proposed for a number of different neurodegenerative disorders, including Alzheimer's disease (AD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), progressive supranuclear palsy syndrome (PSPS), and Parkinson's disease (PD). All of these disorders represent targets for ongoing and future RCTs. Rates of hippocampal atrophy and ventricular expansion provide excellent biomarkers of disease progression in AD, and may also provide biomarkers in prodromal and preclinical phases of the disease, as well as in DLB. Rates of ventricular expansion also perform well in FTD, although regional frontal and temporal measurements could also be useful. Rates of midbrain atrophy provide the most feasible MRI biomarker in PSPS. In contrast, PD is not associated with specific patterns of cerebral atrophy and further work is needed in order to define useful MRI biomarkers. Sample size calculations using these MRI biomarkers are presented and discussed. Key Messages: Rates of cerebral atrophy provide valuable potential biomarkers of disease progression in neurodegenerative disorders, and have already begun to be utilized as outcome measures in RCTs. Measurements from other structural and functional MRI modalities require more longitudinal validation, but may prove to be useful in the future.

UR - http://www.scopus.com/inward/record.url?scp=84980373511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980373511&partnerID=8YFLogxK

U2 - 10.1159/000445419

DO - 10.1159/000445419

M3 - Article

VL - 39

SP - 101

EP - 108

JO - Frontiers of Neurology and Neuroscience

JF - Frontiers of Neurology and Neuroscience

SN - 1660-4431

ER -